Literature DB >> 9168843

Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression.

S Duty1, J M Brotchie.   

Abstract

Repeated dopamine receptor stimulation in the 6-hydroxydopamine (6-OHDA)-lesioned rat produces a marked enhancement in the behavioral response to a given dose of dopamine agonist. Such treatment also increases the synthesis of preproenkephalin-B (PPE-B) throughout the striatum and preproenkephalin-A (PPE-A) rostrally. To examine the relationship between these changes, 6-OHDA-lesioned rats were treated with apomorphine (5 mg/kg) twice-daily. Between 0.5 and 7 days treatment, behavior was monitored and the levels of PPE-A and PPE-B mRNA were determined by in situ hybridization. A single injection of apomorphine induced a well-known rotational response contraversive to the lesion (314 +/- 22 rotations h-1). However, with repeated injection, the response to apomorphine was markedly enhanced, being significantly higher on Days 3 (704 +/- 60 rotations h-1), 5 (1354 +/- 104 rotations h-1), and 7 (1680 +/- 117 rotations h-1). In the lesioned caudate-putamen, but not in the nucleus accumbens, PPE-B expression rose in a manner that was temporally correlated with the enhanced locomotor response to apomorphine. PPE-A expression in the lesioned striatum, significantly increased only after 7 days treatment, did not correlate with the behavioral response. In conclusion, PPE-B may contribute to the development of behavioral supersensitivity following repeated dopamine-replacement therapy in animal models of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9168843     DOI: 10.1006/exnr.1997.6431

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  3 in total

1.  Effects of the novel glycopeptide opioid agonist MMP-2200 in preclinical models of Parkinson's disease.

Authors:  Xu Yue; Torsten Falk; Leslie A Zuniga; Lajos Szabò; Frank Porreca; Robin Polt; Scott J Sherman
Journal:  Brain Res       Date:  2011-07-23       Impact factor: 3.252

2.  CNS penetration of the opioid glycopeptide MMP-2200: a microdialysis study.

Authors:  Omar S Mabrouk; Torsten Falk; Scott J Sherman; Robert T Kennedy; Robin Polt
Journal:  Neurosci Lett       Date:  2012-11-02       Impact factor: 3.046

Review 3.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.